Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carc...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, David F., Lee, Jae-Lyun, Bjarnason, Georg A., Larkin, James M. G., Gafanov, Rustem A., Kochenderfer, Mark D., Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S., Alonso-Gordoa, Teresa, Cho, Daniel C., Geertsen, Poul F., Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F., Schloss, Charles, Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078336/
https://www.ncbi.nlm.nih.gov/pubmed/33529051
http://dx.doi.org/10.1200/JCO.20.02363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078336/
https://www.ncbi.nlm.nih.gov/pubmed/33529051
http://dx.doi.org/10.1200/JCO.20.02363

Ejemplares similares